14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $5.34 $19.02 Friday, 15th Mar 2024 NLTX stock ended at $3.49. During the day the stock fluctuated 0% from a day low at $3.49 to a day high of $3.49.
90 days $17.30 $19.02
52 weeks $16.32 $20.85

Historical Neoleukin Therapeutics Inc prices

Date Open High Low Close Volume
Mar 15, 2024 $3.49 $3.49 $3.49 $3.49 0
Mar 14, 2024 $3.49 $3.49 $3.49 $3.49 0
Mar 13, 2024 $3.49 $3.49 $3.49 $3.49 0
Mar 12, 2024 $3.49 $3.49 $3.49 $3.49 0
Mar 11, 2024 $3.49 $3.49 $3.49 $3.49 0
Mar 08, 2024 $3.49 $3.49 $3.49 $3.49 0
Mar 07, 2024 $3.49 $3.49 $3.49 $3.49 0
Mar 06, 2024 $3.49 $3.49 $3.49 $3.49 0
Mar 05, 2024 $3.49 $3.49 $3.49 $3.49 0
Mar 04, 2024 $3.49 $3.49 $3.49 $3.49 0
Mar 01, 2024 $3.49 $3.49 $3.49 $3.49 0
Feb 29, 2024 $3.49 $3.49 $3.49 $3.49 0
Feb 28, 2024 $3.49 $3.49 $3.49 $3.49 0
Feb 27, 2024 $3.49 $3.49 $3.49 $3.49 0
Feb 26, 2024 $3.49 $3.49 $3.49 $3.49 0
Feb 23, 2024 $3.49 $3.49 $3.49 $3.49 0
Feb 22, 2024 $3.49 $3.49 $3.49 $3.49 0
Feb 21, 2024 $3.49 $3.49 $3.49 $3.49 0
Feb 20, 2024 $3.49 $3.49 $3.49 $3.49 0
Feb 16, 2024 $3.49 $3.49 $3.49 $3.49 0
Feb 15, 2024 $3.49 $3.49 $3.49 $3.49 0
Feb 14, 2024 $3.49 $3.49 $3.49 $3.49 0
Feb 13, 2024 $3.49 $3.49 $3.49 $3.49 0
Feb 12, 2024 $3.49 $3.49 $3.49 $3.49 0
Feb 09, 2024 $3.49 $3.49 $3.49 $3.49 0
Click to get the best stock tips daily for free!

About Neoleukin Therapeutics Inc

Neoleukin Therapeutics Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aqui... NLTX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT